SIGA Technologies — Three and Nine Months Ended September 30, 2026 Earnings Summary

Financial Performance:

• Total revenues for the three months ended September 30, 2026, were $1.3 million, down from $2.6 million in the same period in 2025.
• Total revenues for the nine months ended September 30, 2026, were $48.6 million, down from $90.8 million in the same period in 2025.
• Product sales for the three months ended September 30, 2026, were $0.2 million, compared to $0.9 million in 2025.
• Product sales for the nine months ended September 30, 2026, were $41.6 million, compared to $85.8 million in 2025.
• Operating loss for the three months ended September 30, 2026, was $6.5 million, an improvement from an operating loss of $10.2 million in 2025.
• Operating income for the nine months ended September 30, 2026, was $2.1 million, down from $33.2 million in 2025.
• Net loss for the three months ended September 30, 2026, was $2.9 million, compared to a net loss of $6.4 million in 2025.
• Net income for the nine months ended September 30, 2026, was $6.1 million, down from $28.7 million in 2025.
• Diluted loss per share for the three months ended September 30, 2026, was $0.04, compared to $0.09 in 2025.
• Diluted income per share for the nine months ended September 30, 2026, was $0.09, down from $0.40 in 2025.
• Cash and cash equivalents were $116.4 million as of September 30, 2026, down from $155.0 million as of December 31, 2025.
• Total assets were $172.6 million as of September 30, 2026, down from $219.5 million as of December 31, 2025.
• Total liabilities were $9.4 million as of September 30, 2026, down from $20.6 million as of December 31, 2025.
• Deferred IV TPOXX revenue was $0 as of September 30, 2026, compared to $10.2 million as of December 31, 2025.

Business Segments and Product Lines:

• The Company delivered approximately $13 million of oral TPOXX to two international customers during the nine months ended September 30, 2026.
• The Company delivered approximately $26 million of IV TPOXX to the U.S. Strategic National Stockpile (SNS) under the 19C contract during the nine months ended September 30, 2026, fulfilling the final procurement order under that contract.
• Research and development revenue was $1.1 million for the three months ended September 30, 2026, compared to $1.7 million in 2025.
• Research and development revenue was $6.9 million for the nine months ended September 30, 2026, compared to $4.9 million in 2025.

Other Key Points:

• In October 2026, the Canadian Department of National Defence awarded a $15 million procurement contract for oral TPOXX, providing for purchases up to approximately $15 million by March 31, 2031, with $9 million in firm commitments over the first three years and $6 million subject to option exercise.
• A special cash dividend of $0.60 per share was declared on March 26, 2026, and paid on April 23, 2026.
• Dennis Hrubry, Ph.D., Executive Vice President and Chief Scientific Officer, retired effective November 9, 2026, after more than 30 years with the Company, and will continue in an advisory capacity.
• The Company is actively pursuing opportunities with other international governments to diversify its customer base while working with the U.S. Government toward a new TPOXX procurement contract.
• Forward-looking statements include risks regarding the ability to secure additional U.S. Government contracts, completion of the 19C BARDA Contract, development of the international biodefense market, product efficacy and safety, supply chain delays, regulatory approvals, patent challenges, and economic or political conditions.